- University of Sheffield spinout company Rinri Therapeutics has announced a new, minimally invasive surgical technique for delivering a novel regenerative cell therapy directly to the auditory nerve
- The new approach allows for nerve access through the inner ear's round window, avoiding highly invasive procedures previously required to reach deep skull areas
- The technique will be used in Rinri’s upcoming first human trial for Rincell-1, their lead product for hearing loss treatment, set to begin next year
University of Sheffield spinout company, Rinri Therapeutics, has announced an innovative surgical method set to revolutionise treatment for hearing loss.
Rinri Therapeutics, a company focused on developing new treatments for hearing loss using regenerative cell therapy, has announced an innovative surgical method to deliver treatments directly to the nerve that connects the inner ear to the brain.
The new technique recently published in Scientific Reports (a high-profile journal from the prestigious Nature portfolio) was developed as a safe and minimally invasive way to deliver treatments directly to the nerve that connects the inner ear to the brain. It will be used in Rinri’s upcoming first human trial for Rincell-1, their leading product aimed at treating hearing loss, which is expected to begin next year.
Hearing problems like age-related hearing loss and auditory neuropathy spectrum disorder (ANSD) affect over 100 million people globally. These conditions happen when the nerve connections in the inner ear deteriorate. A cell therapy that can rebuild these connections could significantly improve hearing and quality of life for patients.
Rinri's underlying technology is based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield. It seeks to reverse sensorineural hearing loss through the repair of the damaged cytoarchitecture in the inner ear.
Previously, accessing these nerves required highly invasive surgery, as they are located deep within the skull. Funded by Rinri Therapeutics, researchers from the universities of Sheffield and Nottingham, King’s College London, Canada and Sweden, have now discovered a new safe and reliable way to access these nerves through the inner ear’s round window – a much less invasive and more accessible approach.
Professor Marcelo Rivolta, from the University of Sheffield’s School of Biosciences, said: "This paper describes a novel surgical pathway to access the human cochlear nerve, opening up an important route to deliver new therapeutic agents, such as cells. For us, it is a fantastic achievement and it consolidates our plans of commencing critical trials to treat neural hearing loss in the very near future."
Rincell-1 is designed to restore nerve connections between the inner ear and brain, offering a groundbreaking treatment for severe age-related hearing loss and auditory neuropathy. The treatment was developed using Rinri’s OSPREY™ platform, which creates ready-to-use regenerative cell therapies. Following strong preclinical results showing safety and effectiveness, Rinri plans to start human trials for Rincell-1 in 2025.
Dr Simon Chandler, CEO of Rinri Therapeutics, said: “The novel access route developed in elegant work by this team of leading hearing loss researchers and surgeons makes the delivery of transformative cell therapies like Rincell-1 possible.
“We’re delighted that the first-in-human trial for our lead product is on track to start in 2025, bringing the potential to transform the lives of people with neural hearing loss.”
Professor Doug Hartley, University of Nottingham, Chief Medical Officer at Rinri Therapeutics said: ‘Neural hearing loss has a significantly detrimental effect on the ability to understand speech, particularly with background noise, with a significant detrimental impact on quality of life. The novel surgical access devised by this research collaboration provides a therapeutic pathway to the cochlear nerve which is expected to be highly valuable in clinical practice as part of regenerative cell therapy for this global unmet medical need.’
